Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands

Eui Sang Chung, Sunil Kumar Chauhan, Yiping Jin, Shintaro Nakao, Ali Hafezi-Moghadam, Nico Van Rooijen, Qiang Zhang, Lu Chen, Reza Dana

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Vascular endothelial growth factor receptor (VEGFR)-2 is a major stimulator of hemangiogenesis (HA), whereas VEGFR-3 stimulates lymphangiogenesis (LA). Contrary to this understanding, we demonstrate that implantation of pellets containing VEGFR-3-specific ligands (VEGF-C156S and recombinant murine VEGF-D) into the corneal stroma induce not only LA but also robust HA characterized by blood vessels that are positive for VEGFR-3 expression. The implantation of pellets containing VEGFR-3-specific ligands also leads to the recruitment of VEGF-A-secreting macrophages. Depletion of these infiltrating macrophages using clodronate-liposome administration shows a significant reduction in HA as well as LA. Blockade of either VEGFR-2 or VEGFR-3 signaling reduces both HA and LA; however, the percent reduction of HA is greater in the VEGFR-2 blockade group. In addition, in the VEGFR-3 blockade group, the percent reduction of HA is significantly greater with VEGFR-3-specific ligands than that by VEGF-A or VEGF-C. Collectively, our data suggest that VEGFR-3-specific signaling can induce new blood vessels, to which macrophages contribute a major role, and signify its potential as an additional therapeutic target to the existing VEGF-A/VEGFR-2 signaling-based antiangiogenesis strategies.

Original languageEnglish
Pages (from-to)1984-1992
Number of pages9
JournalAmerican Journal of Pathology
Volume175
Issue number5
DOIs
Publication statusPublished - Jan 1 2009

Fingerprint

Vascular Endothelial Growth Factor Receptor-3
Macrophages
Lymphangiogenesis
Ligands
Vascular Endothelial Growth Factor Receptor-2
Vascular Endothelial Growth Factor A
Blood Vessels
Vascular Endothelial Growth Factor D
Clodronic Acid
Vascular Endothelial Growth Factor C
Corneal Stroma
Liposomes

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands. / Chung, Eui Sang; Chauhan, Sunil Kumar; Jin, Yiping; Nakao, Shintaro; Hafezi-Moghadam, Ali; Van Rooijen, Nico; Zhang, Qiang; Chen, Lu; Dana, Reza.

In: American Journal of Pathology, Vol. 175, No. 5, 01.01.2009, p. 1984-1992.

Research output: Contribution to journalArticle

Chung, ES, Chauhan, SK, Jin, Y, Nakao, S, Hafezi-Moghadam, A, Van Rooijen, N, Zhang, Q, Chen, L & Dana, R 2009, 'Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands', American Journal of Pathology, vol. 175, no. 5, pp. 1984-1992. https://doi.org/10.2353/ajpath.2009.080515
Chung, Eui Sang ; Chauhan, Sunil Kumar ; Jin, Yiping ; Nakao, Shintaro ; Hafezi-Moghadam, Ali ; Van Rooijen, Nico ; Zhang, Qiang ; Chen, Lu ; Dana, Reza. / Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands. In: American Journal of Pathology. 2009 ; Vol. 175, No. 5. pp. 1984-1992.
@article{94ee92d9f4b34f23b1680d7131f1f937,
title = "Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands",
abstract = "Vascular endothelial growth factor receptor (VEGFR)-2 is a major stimulator of hemangiogenesis (HA), whereas VEGFR-3 stimulates lymphangiogenesis (LA). Contrary to this understanding, we demonstrate that implantation of pellets containing VEGFR-3-specific ligands (VEGF-C156S and recombinant murine VEGF-D) into the corneal stroma induce not only LA but also robust HA characterized by blood vessels that are positive for VEGFR-3 expression. The implantation of pellets containing VEGFR-3-specific ligands also leads to the recruitment of VEGF-A-secreting macrophages. Depletion of these infiltrating macrophages using clodronate-liposome administration shows a significant reduction in HA as well as LA. Blockade of either VEGFR-2 or VEGFR-3 signaling reduces both HA and LA; however, the percent reduction of HA is greater in the VEGFR-2 blockade group. In addition, in the VEGFR-3 blockade group, the percent reduction of HA is significantly greater with VEGFR-3-specific ligands than that by VEGF-A or VEGF-C. Collectively, our data suggest that VEGFR-3-specific signaling can induce new blood vessels, to which macrophages contribute a major role, and signify its potential as an additional therapeutic target to the existing VEGF-A/VEGFR-2 signaling-based antiangiogenesis strategies.",
author = "Chung, {Eui Sang} and Chauhan, {Sunil Kumar} and Yiping Jin and Shintaro Nakao and Ali Hafezi-Moghadam and {Van Rooijen}, Nico and Qiang Zhang and Lu Chen and Reza Dana",
year = "2009",
month = "1",
day = "1",
doi = "10.2353/ajpath.2009.080515",
language = "English",
volume = "175",
pages = "1984--1992",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Contribution of macrophages to angiogenesis induced by vascular endothelial growth factor receptor-3-specific ligands

AU - Chung, Eui Sang

AU - Chauhan, Sunil Kumar

AU - Jin, Yiping

AU - Nakao, Shintaro

AU - Hafezi-Moghadam, Ali

AU - Van Rooijen, Nico

AU - Zhang, Qiang

AU - Chen, Lu

AU - Dana, Reza

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Vascular endothelial growth factor receptor (VEGFR)-2 is a major stimulator of hemangiogenesis (HA), whereas VEGFR-3 stimulates lymphangiogenesis (LA). Contrary to this understanding, we demonstrate that implantation of pellets containing VEGFR-3-specific ligands (VEGF-C156S and recombinant murine VEGF-D) into the corneal stroma induce not only LA but also robust HA characterized by blood vessels that are positive for VEGFR-3 expression. The implantation of pellets containing VEGFR-3-specific ligands also leads to the recruitment of VEGF-A-secreting macrophages. Depletion of these infiltrating macrophages using clodronate-liposome administration shows a significant reduction in HA as well as LA. Blockade of either VEGFR-2 or VEGFR-3 signaling reduces both HA and LA; however, the percent reduction of HA is greater in the VEGFR-2 blockade group. In addition, in the VEGFR-3 blockade group, the percent reduction of HA is significantly greater with VEGFR-3-specific ligands than that by VEGF-A or VEGF-C. Collectively, our data suggest that VEGFR-3-specific signaling can induce new blood vessels, to which macrophages contribute a major role, and signify its potential as an additional therapeutic target to the existing VEGF-A/VEGFR-2 signaling-based antiangiogenesis strategies.

AB - Vascular endothelial growth factor receptor (VEGFR)-2 is a major stimulator of hemangiogenesis (HA), whereas VEGFR-3 stimulates lymphangiogenesis (LA). Contrary to this understanding, we demonstrate that implantation of pellets containing VEGFR-3-specific ligands (VEGF-C156S and recombinant murine VEGF-D) into the corneal stroma induce not only LA but also robust HA characterized by blood vessels that are positive for VEGFR-3 expression. The implantation of pellets containing VEGFR-3-specific ligands also leads to the recruitment of VEGF-A-secreting macrophages. Depletion of these infiltrating macrophages using clodronate-liposome administration shows a significant reduction in HA as well as LA. Blockade of either VEGFR-2 or VEGFR-3 signaling reduces both HA and LA; however, the percent reduction of HA is greater in the VEGFR-2 blockade group. In addition, in the VEGFR-3 blockade group, the percent reduction of HA is significantly greater with VEGFR-3-specific ligands than that by VEGF-A or VEGF-C. Collectively, our data suggest that VEGFR-3-specific signaling can induce new blood vessels, to which macrophages contribute a major role, and signify its potential as an additional therapeutic target to the existing VEGF-A/VEGFR-2 signaling-based antiangiogenesis strategies.

UR - http://www.scopus.com/inward/record.url?scp=73649122428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73649122428&partnerID=8YFLogxK

U2 - 10.2353/ajpath.2009.080515

DO - 10.2353/ajpath.2009.080515

M3 - Article

C2 - 19808642

AN - SCOPUS:73649122428

VL - 175

SP - 1984

EP - 1992

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 5

ER -